Skip to main content
SpringerLink
Log in

Adding tocilizumab cost effective for RA in the UK

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. including certolizumab pegol, etanercept, adalimumab, abatacept, rituximab and infliximab

  2. The study was funded by F. Hoffmann-La Roche Ltd.

Reference

  • Diamantopoulos A, et al. Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK. PharmacoEconomics : 23 May 2014. Available from: URL: http://doi.org/10.1007/s40273-014-0165-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adding tocilizumab cost effective for RA in the UK. PharmacoEcon Outcomes News 704, 3 (2014). https://doi.org/10.1007/s40274-014-1279-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1279-z

Search

Navigation